Antibiotics Need Additional Development Incentives, FDA Says
Executive Summary
Government incentives likely will be necessary to rejuvenate the development pipeline for antibiotics, Janet Woodcock, director of FDA's Center for Drug Evaluation and Research, told a congressional committee